A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL



Status:Recruiting
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:60 - Any
Updated:3/16/2015
Start Date:March 2012
End Date:August 2017
Contact:Dennis Kim, MD
Email:Dennis.Kim@sppirx.com
Phone:949-743-9229

Use our guide to learn which trials are right for you!

Phase 3 Study of Study to Evaluate Marqibo® in the Combination Chemotherapy in the Treatment of Subjects >or=60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

A phase 3 study in the treatment of subjects >or= 60 years old with newly diagnosed acute
lymphoblastic leukemia (ALL).

A phase 3, multicenter, randomized study to evaluate the substitution of Marqibo®
(Vincristine Sulfate Liposomes Injection, VSLI) for standard Vincristine Sulfate Injection
(VSI) in the induction, intensification, and maintenance phases of combination chemotherapy
in the treatment of subjects >or= 60 years old with newly diagnosed acute lymphoblastic
leukemia (ALL).

Inclusion Criteria:

Have provided written, signed, and dated informed consent to participate in the study, in
accordance with the ICH GCP Guideline E6 and all applicable local regulations.Are age
>or=60 years (at the time of providing informed consent).

Have newly diagnosed, histologically proven, untreated Philadelphia chromosome-negative
(Ph-) ALL, with >or= 5% bone marrow blasts.

Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Have a life
expectancy >or= 3 months.

Have renal and liver function as defined below within 14 days, inclusive, prior to study
enrollment, unless the abnormality is considered attributable to leukemia:

Total bilirubin ≤ 2.0 x the upper limit of normal (ULN), unless the subject has a known
diagnosis of Gilbert's disease Aspartate transaminase (AST, SGOT) or alanine transaminase
(ALT, SGPT) ≤ 3 x ULN Serum creatinine ≤ 1.5 x ULN. Not have had major surgery within 4
weeks before the planned start of treatment.

If female, are post-menopausal, surgically sterilized, or willing to use acceptable
methods of birth control (eg, hormonal contraceptive, intra-uterine device, diaphragm with
spermicide, condom with spermicide, or abstinence) from the screening visit through 30
days after the last dose of any protocol defined chemotherapeutic agents.

If male and sexually active with a partner of child-bearing potential, agree to use an
acceptable barrier method for contraception from the screening visit through 30 days after
the last dose of any protocol defined chemotherapeutic agents.

Have the ability and willingness to fully comply with study procedures and restrictions.

-

Exclusion Criteria:

Has had prior systemic chemotherapy (for ALL or other malignancy). Has had prior
vincristine for any reason. Is planning to undergo stem cell transplantation (SCT) as any
part of first-line therapy for ALL.

Has Burkitt's lymphoma/leukemia. Has Philadelphia chromosome-positive (Ph+) ALL and/or
BCR/ABL rearrangements documented by fluorescent in-situ hybridization (FISH),
cytogenetics, or polymerase chain reaction (PCR).

Has active central nervous system (CNS) disease. Has ongoing neuropathy of any etiology >
Grade 1. Has a history of persistent active neurologic disorders including demyelinating
form of Charcot-Marie-Tooth syndrome, acquired demyelinating disorders, and other
demyelinating conditions.

Prior hydroxyurea (Hydrea®) for the management of any condition other than leukocytosis or
prior hydroxyurea of >7 days duration for the management of leukocytosis (hydroxyurea for
the management of leukocytosis must be planned to be tapered off before or on Day 5 of
Induction).

Has received prior steroids within 7 days before beginning protocol-specified Induction
therapy for reasons other than leukocytosis (steroids for the management of leukocytosis
are allowed but must be planned to be tapered off before or on Day 5 of Induction).

Has an active serious infection not controlled by oral or IV antibiotics or antifungals.

Has received any investigational therapy within 28 days before beginning any
protocol-defined chemotherapeutic treatment.

-
We found this trial at
15
sites
3855 Health Sciences Dr,
La Jolla, California 92093
(858) 822-6100
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
4100 John R
Detroit, Michigan 48201
800-527-6266
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1365 Clifton Rd NE
Atlanta, Georgia 30322
(404) 778-1900
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
?
mi
from
Houston, Texas, TX
Click here to add this to my saved trials
Los Angeles, California 90095
(310) 825-4321
UCLA UCLA's primary purpose as a public research university is the creation, dissemination, preservation and...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New York, New York
?
mi
from
New York, NY
Click here to add this to my saved trials
4242 Dewey Ave
Omaha, Nebraska 68105
(800) 922-0000
Nebraska Medical Center Formed in 1997 by combining the operations of University Hospital, Bishop Clarkson...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials